Gaps in evidence for the use of medically authorized cannabis: Ontario and Alberta, Canada
Abstract Background: With legal access to medical cannabis in Canada since 2001, there is a need to fully characterize its…
central spasticity
Cannabinoid Activity—Is There a Causal Connection to Spasmolysis in Clinical Studies?
Abstract Cannabinoid drugs are registered for postoperative nausea and emesis, Tourette syndrome and tumor-related anorexia, but are also used for…
Selective Endocannabinoid Reuptake Inhibitor WOBE437 Reduces Disease Progression in a Mouse Model of Multiple Sclerosis
Abstract The modulation of the endocannabinoid system (ECS) has shown positive results in animal models of multiple sclerosis (MS) and…
The Therapeutic Potential and Usage Patterns of Cannabinoids in People with Spinal Cord Injuries: A Systematic Review
Abstract Background: People with spinal cord injuries (SCI) commonly experience pain and spasticity; limitations of current treatments have generated interest…
The Broad Concept of “Spasticity-Plus Syndrome” in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms
Abstract Multiple sclerosis (MS) pathology progressively affects multiple central nervous system (CNS) areas. Due to this fact, MS produces a…
Cannabis-based product use in a multiple sclerosis cohort
Abstract Objective: The objective of this study was to characterize the use of cannabis-based products (CBPs) by multiple sclerosis (MS)…
Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies
Abstract Background/purpose: Spasticity is one of the most common symptoms in people with multiple sclerosis (MS). Conventional anti-spasticity agents have…
The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis‐related spasticity
Abstract Background: Driving ability is a key function for the majority of patients with multiple sclerosis (MS) to help maintain…
The role of Sativex in robotic rehabilitation in individuals with multiple sclerosis
Abstract Introduction: Currently, none of the available multiple sclerosis (MS) disease-modifying medications has been shown to stop or reverse gait…
An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray
Abstract The global exposure of Sativex® (Δ9-tetrahydrocannabinol [THC]:cannabidiol [CBD], nabiximols) is estimated to be above 45,000 patient-years since it was…